tiprankstipranks
SAB Biotherapeutics (SABS)
NASDAQ:SABS
US Market
SABS
SAB Biotherapeutics
RESEARCH TOOLSreports
Want to see SABS full AI Analyst Report?

SAB Biotherapeutics (SABS) Income Statement

327 Followers

SAB Biotherapeutics Income Statement

Last quarter (Q4 2025), SAB Biotherapeutics's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q4, SAB Biotherapeutics's net income was $-16.86M. See SAB Biotherapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Mar 25Dec 23Mar 23Dec 21
Total Revenue
$ 0.00$ 1.32M$ 2.24M$ 23.90M$ 60.88M
Gross Profit
$ -3.08M$ -3.47M$ -1.51M$ 20.61M$ 59.22M
Operating Expenses
$ 45.87M$ 39.44M$ 36.57M$ 49.53M$ 72.62M
Depreciation and Amortization
$ 3.08M$ 4.79M$ 3.75M$ 3.29M$ 1.65M
EBITDA
$ 16.60M$ -28.99M$ -38.13M$ -15.12M$ -15.20M
Operating Income
$ -48.95M$ -42.91M$ -38.08M$ -28.92M$ -13.39M
Other Income/Expenses
$ 62.23M$ 8.81M$ -4.12M$ 10.20M$ -3.75M
Pretax Income
$ 13.27M$ -34.11M$ -42.19M$ -18.72M$ -17.14M
Net Income
$ 13.27M$ -34.11M$ -42.19M$ -18.74M$ -17.14M
Per Share Metrics
Basic EPS
$ 0.22$ -3.68$ -7.64$ -4.31$ -3.94
Diluted EPS
$ -0.79$ -3.68$ -7.64$ -4.31$ -6.30
Weighted Average Shares Outstanding
 19.31M 9.26M 5.52M 4.35M 4.35M
Weighted Average Shares Outstanding (Diluted)
 61.34M 9.26M 5.52M 4.35M 2.73M
Currency in USD

SAB Biotherapeutics Earnings and Revenue History